LORAZEPAM TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

LORAZEPAM

Beszerezhető a:

SIVEM PHARMACEUTICALS ULC

ATC-kód:

N05BA06

INN (nemzetközi neve):

LORAZEPAM

Adagolás:

2MG

Gyógyszerészeti forma:

TABLET

Összetétel:

LORAZEPAM 2MG

Az alkalmazás módja:

ORAL

db csomag:

100/1000

Recept típusa:

Targeted (CDSA IV)

Terápiás terület:

BENZODIAZEPINES

Termék összefoglaló:

Active ingredient group (AIG) number: 0110731002; AHFS:

Engedélyezési státusz:

CANCELLED POST MARKET

Engedély dátuma:

2016-09-08

Termékjellemzők

PRODUCT MONOGRAPH
LORAZEPAM
LORAZEPAM TABLETS USP
0.5 MG, 1 MG AND 2 MG
ANXIOLYTIC-SEDATIVE
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUÉBEC
H4R 2P7
DATE OF PREPARATION: AUGUST 20, 2014
CONTROL NO. : 176952
Lorazepam Product Monograph
Page 2 of 24
TABLE OF CONTENTS
PRESCRIBING INFORMATION
.............................................................................................
1
ACTIONS AND CLINICAL PHARMACOLOGY
.......................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
6
CONTRAINDICATIONS
..........................................................................................................
6
WARNINGS
...........................................................................................................................
6
PRECAUTIONS
......................................................................................................................
7
DRUG INTERACTIONS
..........................................................................................................
9
ADVERSE REACTIONS
.......................................................................................................
10
SYMPTOMS AND TREATMENT OF OVERDOSE
............................................................... 11
DOSAGE AND ADMINISTRATION
.......................................................................................
11
AVAILABILITY OF DOSAGE FORMS
..................................................................................
12
PHARMACEUTICAL INFORMATION
...................................................................................
13
PHARMACOLOGY................................................................................................................
14
TOXICOLOGY.......................................................................................................................
16
REFERENCES
.................................................